Women Health Care Executives Names Genomic Health President Kimberly Popovits as 'Woman of...( Popovits to be Honored at Gala Dinn...),Health

Popovits to be Honored at Gala Dinner in San Francisco on June 12, 2008

SAN FRANCISCO and REDWOOD CITY, Calif., Mar. 3 /PRNewswire/ -- Women Health Care Executives of Northern California (WHCE) announced today that Kimberly Popovits, president and chief operating officer of Redwood City-based Genomic Health, Inc., has been named its 2008 "Woman of the Year." Popovits will be honored at a gala dinner to be held at the Carnelian Room atop the Bank of America building in San Francisco on June 12, 2008.

"The WHCE board of directors always has many impressive candidates to choose from, and this year was no exception," said WHCE President Kimberly Werninghaus Blair. "But Kim Popovits' professional accomplishments, the many people and lives she has impacted, and the contributions her work has made to the larger medical and biopharmaceutical communities gave us a clear choice for our 2008 Woman of the Year."

Popovits has been a leader in the biopharmaceutical industry for more than 25 years. She spent 15 years as head of commercial operations at Genentech, where she led the successful commercialization of 14 new therapies, including Herceptin(R), the cancer treatment drug that revolutionized the way doctors treat a particularly aggressive form of breast cancer. Herceptin is often touted as the first "targeted therapy," that is, one based on an individual's unique genetic profile, and that it has helped to usher in the age of "personalized medicine." As Genomic Health's president and chief operating officer, Popovits helped bring yet another first-of-its-kind product to women: the Oncotype(R) DX breast cancer test, which predicts whether a woman's cancer will return and how likely she is to benefit from chemotherapy based on the genomic makeup of her tumor. Thanks to her pioneering mentality and perseverance with physicians and payers, more than 46,000 women to date have benefited from the individualized information that Oncotype DX provides in maki
'/>"/>